KYNTRA BIO, INC. Loss Contingency, Receivable, Current
KYNTRA BIO, INC. (KYNB) had Loss Contingency, Receivable, Current of $0 as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Commitment and Contingencies › Loss Contingency
us-gaap:LossContingencyReceivableCurrent · last filed 2026-03-16
- 2025-12-31: Loss Contingency, Receivable, Current $0.00.
- 2025-09-30: Loss Contingency, Receivable, Current $0.00.
- 2025-06-30: Loss Contingency, Receivable, Current $0.00.
- 2025-03-31: Loss Contingency, Receivable, Current $0.00.
| Period end | Loss Contingency, Receivable, Current |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-16 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-12 |
| 2024-12-31 | $28.50M 10-K · filed 2026-03-16 |
| 2024-09-30 | $28.50M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $28.50M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $28.50M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $28.50M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |